The incidence and impact of thrombocytopenia in myelodysplasia syndromes

Cancer

Volumn 109, Issue 9, 2007, Pages 1705-1714

  Kantarjian, Hagop ^a,f   Giles, Francis ^a   List, Alan ^b   Lyons, Roger ^c   Sekeres, Mikkael A ^d   Pierce, Sherry ^a   Deuson, Robert ^e   Leveque, Joseph ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e AMGEN INC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

International Prognostic Scoring System; Myelodysplasia syndrome; Platelets; Thrombocytopenia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ARSENIC TRIOXIDE; AZACITIDINE; CALCITRIOL; CYCLOSPORIN; CYTARABINE; DANAZOL; ETANERCEPT; IDARUBICIN; INTERLEUKIN 3; ISOTRETINOIN; LENALIDOMIDE; MENATETRENONE; PEGYLATED RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PENTOXIFYLLINE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 6; RETINOIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ARTHRALGIA; BLEEDING; CHILL; CONJUNCTIVITIS; FATIGUE; FEVER; FLUID RETENTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERSENSITIVITY REACTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LUNG EDEMA; MYALGIA; MYELODYSPLASTIC SYNDROME; PAPILLEDEMA; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK;

HUMANS; INCIDENCE; MYELODYSPLASTIC SYNDROMES; THROMBOCYTOPENIA;

EID: 34247646400     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22602     Document Type: Review

References (92)

1. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73:405-410.
2. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002;136-161.
3. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1-16.
4. Aul C, Germing U, Gattermann N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leukemia Res. 1998;22:93-100.
5. Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H. Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol. 1995;61:17-22.
6. Cartwright RA. Incidence and epidemiology or the myelodysplastic syndromes. In: Mufti GJ, Dalton DAG, eds. The Myelodysplastic Syndromes. Edinburgh: Churchill Livingtone; 1992:22-31.
7. Maynadie M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74:288-290.
8. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995;54:153-156.
9. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358-367.
10. Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M. Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leukemia Res. 1998;22:205-208.
11. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994;87:743-745.
12. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-352.
13. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71-86.
14. Friedberg JW, Neuberg D, Stone RM, et al. Outcomes in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3128-3135.
15. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006;24:3604-3610.
16. Dalamaga M, Petridou E, Cook FE, Trichopoulos D. Risk factors for myelodysplastic syndromes: a case-control study in Greece. Cancer Causes Control. 2002;13:603-608.
17. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187-200.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
20. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
21. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe E, Harris N, Stein H, eds. WHO Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001: 61-73.
22. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
23. Greenberg P, Anderson J, de Witte T, et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol. 2000;18:3447-3452.
24. Doll DC, List AF. Myelodysplastic syndromes. West J Med. 1989;151:161-167.
25. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
26. Weisdorf DJ, Oken MM, Johnson GJ, Rydell RE. Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol. 1983;55:691-700.
27. Tricot G, Vlietinck R, Boogaerts MA, et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol. 1985;60:19-32.
28. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica. 1998;83:543-549.
29. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.
30. Maldonado JE, Pierre RV. The platelets in preleukemia and myelomonocytic leukemia. Ultrastructural cytochemistry and cytogenetics. Mayo Clin Proc. 1975;50:573-587.
31. Lintula R, Rasi V, Ikkala E, Borgstrom GH, Vuopio P. Platelet function in preleukaemia. Scand J Haematol. 1981;26:65-71.
32. Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndrome: clinical features. Semin Hematol. 1996;33:177-185.
33. Lee ST, Jang JH, Suh HC, Hahn JS, Ko YW, Min YH. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2001;68:237-245.
34. Grossi A, Musto P, Santini V, et al. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica. 2002;87:322-323.
35. Hoffken K, Overkamp F, Stirbu J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie. 1990;13:33-37.
36. Hofmann WK, Seipelt G, Ottmann OG, et al. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol. 2000;79:255-258.
37. Ganser A, Seipelt G, Verbeek W, et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia. 1994;8:369-375.
38. Marini B, Bassan R, Barbui T. Therapeutic efficacy of danazol in myelodysplastic syndromes. Eur J Cancer Clin Oncol. 1988;24:1481-1489.
39. Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-transretinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol. 1996;72:237-244.
40. Koeffler HP, Hirji K, Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep. 1985;69:1399-1407.
41. Mellibovsky L, Diez A, Perez-Vila E, et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol. 1998;100:516-520.
42. Buzaid AC, Garewal HS, Lippman SM, Durie BG, Katakkar SB, Greenberg BR. Danazol in the treatment of myelodysplastic syndromes. Eur J Haematol. 1987;39:346-348.
43. Miller AM, Noyes WE, Taetle R, List AF. Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome. Leukemia Res. 1999;23:77-83.
44. Hofmann WK, Ganser A, Seipelt G, et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinole acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol. 1999;78:125-130.
45. Grossi A, Fabbri A, Santini V, et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica. 2000;85:367-371.
46. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinole acid in patients with myelodysplastic syndromes. Blood. 2002;99:1578-1584.
47. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
48. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leukemia Res. 2003;27:783-788.
49. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705.
50. van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leukemia Res. 2004;28:785-790.
51. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002;87:1286-1306.
52. Mittelman M, Sokolover N, Zeidman A, Redlich O, Cohen A, Fradin Z. Platelet aggregation and its clinical significance in the myelodysplastic syndromes. Leukemia Res. 1999; 23(suppl 1):s24.
53. Kezuka T, Usui N, Suzuki E, Wakasugi K, Usui M. Ocular complications in myelodysplastic syndromes as preleukemic disorders. Jpn J Ophthalmol. 2005;49:377-383.
54. Wattel E, Cambier N, Caulier MT, Sautiere D, Bauters F, Fenaux P. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol. 1994;87:205-208.
55. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
56. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7 (suppl 1):21-29.
57. Powell BL, Capizzi RL, Jackson DV, et al. Low dose Ara-C for patients with myelodysplastic syndromes. Leukemia. 1988;2:153-156.
58. Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B. Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol. 1997;20:189-192.
59. Picozzi VJ Jr, Swanson GF, Morgan R, Hecht F, Greenberg PL. 13-Cis retinole acid treatment for myelodysplastic syndromes. J Clin Oncol. 1986;4:589-595.
60. Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer. 2003;98:2410-2419.
61. Konstantopoulos K, Lauren L, Hast R, Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. Anticancer Res. 1989;9:893-896.
62. Foucar K, Langdon RM, Armitage JO, Olson DB, Carroll TJ Jr. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer. 1985;56:553-561.
63. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leukemia Res. 1999;23:953-959.
64. Lidbeck J. Studies on hemopoietic dysplasia (the preleukemic syndrome). Clinical course and prognostic factors in 42 patients with dysplastic bone marrow. Acta Med Scand. 1980;208:459-462.
65. Beris P. Primary clonal myelodysplastic syndromes. Semin Hematol. 1989;26:216-233.
66. Platzbecker U, Haase M, Herbst R, et al. Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot study. Br J Haematol. 2005;128:625-630.
67. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol. 1991;77:502-508.
68. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45:141-148.
69. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol. 2000;37:3-10.
70. [No authors listed] Consensus conference. Platelet transfusion therapy. JAMA. 1987;257:1777-1780.
71. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493-1499.
72. Yomtovian R, Lazarus HM, Goodnough LT, Hirschler NV, Morrissey AM, Jacobs MR. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 1993;33:902-909.
73. Sepulveda JL. Alloimmunization from transfusions. eMedicine. Updated Jan 13, 2005.
74. Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion. 1997;37:624-630.
75. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251-256.
76. Wolkers WF, Walker NJ, Tablin F, Crowe JH. Human platelets loaded with trehalose survive freeze-drying. Cryobiology. 2001;42:79-87.
77. Cermak J, Belickova M, Michalova K. Combined immunosuppressive treatment in patients with early myelodysplasia. Haematologica. 2005;90(suppl 2):357. Abstract 903.
78. Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leukemia Res. 2004;28:1177-1180.
79. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903.
80. Kantarjian H, Issa J-PJ, Rosenfeld C, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1794-1803.
81. Fenaux P, De Porre P, Raza A, et al. Results of an international phase 2 study of the oral farnesyl transferase inhibitor (FTI) tiptfarnib (Zarnestra, R115777) in patients with high-risk myelodysplastic syndrome (MDS). Haematologica. 2005;90(suppl 2):306. Abstract 770.
82. Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005;16:139-145.
83. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165-4172.
84. Wyeth Pharmaceuticals, Inc. Neumega (oprelvekin) Prescribing Information. Philadelphia, Pa: Wyeth Pharmaceuticals Inc.; 2006.
85. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 1995;85:3066-3076.
86. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
87. Urabe A, Komatsu N, Okomoto T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor on haematopoiesis in patients with aplastic anemia and myelodysplastic syndrome. Exp Hematol. 2001;29:112. Abstract 439.
88. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599-2602.
89. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673-681.
90. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364-368.
91. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519-1538.
92. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10-23.